Shares of Jupiter Neurosciences Inc. (NASDAQ:JUNS) are surging Friday morning as related biotechnology partner PharmAla Biotech Holdings Inc. announced a series of corporate updates, including a newly granted U.S. patent.
Here’s what investors need to know.
Jupiter Neurosciences stock is surging to new heights today. What’s behind JUNS gains?
New Patent Expands IP Portfolio
The United States Patent and Trademark Office granted PharmAla U.S. Patent No. 12,679,817, covering cost-effective, scalable manufacturing processes for single-enantiomer MDMA and MBDB compounds. This patent strengthens the intellectual property foundation for PharmAla’s lead drug candidate, ALA-002.
